A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT04242498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Study identification
- NCT ID
- NCT04242498
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 509 participants
Conditions and interventions
Conditions
Interventions
- Bimekizumab Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2020
- Primary completion
- Nov 8, 2021
- Completion
- Sep 27, 2022
- Last update posted
- May 18, 2026
2020 – 2022
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hs0004 50162 | Fountain Valley | California | 92708 | — |
| Hs0004 50196 | Thousand Oaks | California | 91320 | — |
| Hs0004 50199 | Miami | Florida | 33125 | — |
| Hs0004 50152 | Orange Park | Florida | 32073 | — |
| Hs0004 50144 | Orlando | Florida | 38219 | — |
| Hs0004 50184 | Pembroke Pines | Florida | 33028 | — |
| Hs0004 50193 | Sandy Springs | Georgia | 30328 | — |
| Hs0004 50223 | Savannah | Georgia | 31419 | — |
| Hs0004 50164 | Skokie | Illinois | 60077 | — |
| Hs0004 50234 | Plainfield | Indiana | 46168 | — |
| Hs0004 50178 | Clarkston | Michigan | 48346 | — |
| Hs0004 50105 | St Louis | Missouri | 63110 | — |
| Hs0004 50197 | Henderson | Nevada | 89052 | — |
| Hs0004 50159 | Portsmouth | New Hampshire | 03801 | — |
| Hs0004 50200 | Verona | New Jersey | 07044 | — |
| Hs0004 50237 | Albuquerque | New Mexico | 87106 | — |
| Hs0004 50211 | Durham | North Carolina | 27710 | — |
| Hs0004 50179 | Winston-Salem | North Carolina | 27104 | — |
| Hs0004 50145 | Columbus | Ohio | 43230 | — |
| Hs0004 50202 | Fairborn | Ohio | 45324 | — |
| Hs0004 50150 | Philadelphia | Pennsylvania | 19103 | — |
| Hs0004 50236 | Greenville | South Carolina | 29615 | — |
| Hs0004 50084 | Johns Island | South Carolina | 29425 | — |
| Hs0004 50148 | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04242498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04242498 live on ClinicalTrials.gov.